A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation.

"Conflict of interest Ryosuke Tateishi received grants from Kyowa Hakko Kirin Co., Ltd. outside the submitted work. Masataka Seike received lecture fees from Shionogi & Co., Ltd. outside the submitted work. Outside the submitted work, Masatoshi Kudo received grants from Novartis and Kaken, and lecture and consultancy fees from Eisai. Hideyuki Tamai, Seiji Kawazoe, Katsuaki Tanaka, and Kazuhide Yamamoto have no conflicts of interest to declare. Takayuki Katsube, Toshimitsu Ochiai, Takahiro Fukuhara, and Takeshi Kano are employees of Shionogi & Co., Ltd., which funded this study. Mineo Kurokawa received consultancy fees from Shionogi & Co., Ltd. during the conduct of the study. Outside the submitted work, Mineo Kurokawa received grants from Kyowa Hakko Kirin, Bristol-Myers Squibb, and Astellas. Yukio Osaki received consultancy fees from Shionogi & Co., Ltd. during the conduct of the study. Outside the submitted work, Yukio Osaki received lecture fees from Shionogi & Co., Ltd. Namiki Izumi received consultancy fees from Shionogi & Co., Ltd. during the conduct of the study, and lecture fees from Shionogi & Co., Ltd., Gilead Science, AbbVie, Otsuka, Bayer, and MSD outside the submitted work. Michio Imawari received consultancy fees from Shionogi & Co., Ltd. during the conduct of the study."

"Funding This study was fully funded and sponsored by Shionogi & Co., Ltd. The sponsor was involved in the study concept and design, data analysis and interpretation, writing and critical review of the manuscript, as well as the decision to submit the manuscript for publication."

"Clinical trial registration The study is registered at JapicCTI-121944."